Company Overview and News
Rolls-Royce has been selected to supply its MT30 marine gas turbine to power the Japan Maritime Self Defence Force’s (JMSDF’s) new 30FFM frigate.
As shares of General Electric Company (NYSE:GE) have plunged, the calls for a breakup have grown louder. Bulls see the true value of GE stock as clouded by issues at GE Capital and weakness in divisions such as Lighting and Transportation. With two still-growing businesses — Aviation and Healthcare — plus a 62.5% stake in Baker Hughes a GE Co (NYSE:BHGE), optimists argue there has to be some value in General Electric stock, particularly after a 50%-plus decline from 2016 highs.
RESTON, Va., May 21, 2018 (GLOBE NEWSWIRE) -- Enfission CEO Seth Grae will provide an update at the Nuclear Energy Institute's annual conference May 22 on the development of the company's metallic fuel technology designed to make both existing and new nuclear power plants more efficient and economical. Enfission is a joint venture of Lightbridge Corporation (NASDAQ:LTBR), a nuclear fuel developer, and Framatome, a global supplier of nuclear fuel, plants and services.
The Japan Air Self-Defense Force (JASDF) has deployed a second F-35A Lightning II Joint Strike Fighter to Misawa Air Base in northern Japan.
The U.K. government is offering ¥2 trillion ($18 billion) in loans and other funding to cover a major portion of Hitachi Ltd.’s project to build nuclear reactors in Wales, a source close to the matter said Thursday.
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com
The busy Metro Rail Transit Line 3, which had grabbed headlines for constant breakdowns in recent years, could be restored to its original condition in two and a half years, the Department of Transportation said on Tuesday.
RESTON, Va., May 09, 2018 (GLOBE NEWSWIRE) -- Enfission LLC, a joint venture of Lightbridge Corporation (NASDAQ:LTBR), a nuclear fuel technology company, and Framatome, a leader in nuclear fuel, components and reactor services, today announced its board of directors and management team. The companies officially formed Enfission in January to develop, license and sell nuclear fuel assemblies for both existing and new reactors.
Japan’s top two military manufacturers – Mitsubishi Heavy Industries (MHI) and Kawasaki Heavy Industries (KHI) – have posted mixed results for fiscal year 2017 and have forecasted difficult times ahead for their respective defence divisions.
The report, now available on ASDReports, "Aircraft Doors Market by End User (OEM and Aftermarket), Application (Commercial (NBA, WBA, VLA, RTA, Business Jets) and Military (Transport Aircraft, Helicopter)), Door Type (Passenger, Cargo, Emergency, Access, Landing Gear) - Global Forecast to 2022", The aircraft doors market is projected to grow from USD 3.68 Billion in 2017 to USD 5.22 Billion by 2022, at a CAGR of 7.
Major trading house Itochu Corp. is backing away from a nuclear power plant project in Turkey because of a surge in safety-related costs, sources close to the matter said Tuesday.
Mitsubishi Heavy Industries (MHI) is pushing forward with plans to support greater co-operation across Japan’s aerospace sector.
U.S. defense contractor Lockheed Martin plans to offer Japan a stealth fighter design based on its export-banned F-22 Raptor and advanced F-35 Lightning II aircraft, two sources said.
TOKYO (Reuters) - U.S. defense contractor Lockheed Martin Corp plans to offer Japan a stealth fighter design based on its export-banned F-22 Raptor and advanced F-35 Lightning II aircraft, two sources said.
TOKYO: U.S. defense contractor Lockheed Martin Corp plans to offer Japan a stealth fighter design based on its export-banned F-22 Raptor and advanced F-35 Lightning II aircraft, two sources said.
22h - Asif
Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...
22h - Asif
Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...
as of ET